Last reviewed · How we verify
NCT04638478
PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI
trial testing PRECODE-MRI in Meningioma in 67 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Maastricht Radiation Oncology |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 67 |
| Start date | 8 April 2021 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2029 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- PRECODE-MRI
Conditions studied
- Meningioma — all drugs for Meningioma →
Sponsor
Maastricht Radiation Oncology — full company profile →
Who can join
18 and older, any sex, with Meningioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33% of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors. The 10-year survival rate is 72%. A variety of treatment options is available for symptomatic meningioma including surgical removal with or without radiotherapy or radiotherapy alone. These therapies can have negative impact on cerebral functioning. After high dose radiotherapy for primary or metastatic brain tumors 50-90% of \> 6 months' survivors develop irreversible disabling cognitive decline leading to premature loss of independence, reduced Quality of Life (QOL) as well as significant economic burden both at the individual as societal level. Especially for patients with a good prognosis like benign meningioma, maintaining neurocognitive function is crucial. Understanding the mechanisms underlying radiation induced cognitive decline is complex and which brain areas to spare are an important subject of research. Evaluation methods to assess cognitive function and predict cognitive decline are urgently needed, this will allow the development of optimized treatment strategies with the aim to preserve or even improve cognitive function in meningioma patients. Improvements in the field of neuroimaging techniques (i.e. advanced MRI techniques) have the possibility to identify areas susceptible to cognitive impairment. This allows in the future a more personalized radiation treatment by identifying patients at risk, by optimizing the radiotherapy dose to specific brain regions, that could eventually reduce or prevent, cognitive decline. Improvements in the field of radiotherapy for example by higher precision treatment such proton therapy have potential in obtaining these more individualized strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04638478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meningioma
Currently open trials in the same condition.
- NCT06831461 — Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors · NA · recruiting
- NCT07044076 — Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Men · recruiting
- NCT06132685 — Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial · Phase 2 · recruiting
- NCT06752096 — Robot-Assisted Neurovascular Intervention · NA · recruiting
- NCT06830356 — Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas. · NA · recruiting
Other Maastricht Radiation Oncology trials
Trials by the same sponsor.
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07004582 — Lab Research Using Mini-tumors to Study Prostate Cancer Treatments · not yet recruiting
- NCT06024941 — Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer · Phase 2 · withdrawn
- NCT05182437 — Precision Radiation Treatment for Epilepsy (PRECISION) · NA · active not recruiting
- NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04638478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht Radiation Oncology
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04638478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing